LLBO Lifeline Biotech Inc (CE)

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO), a developer of innovative medical technology, today announced that efforts to establish its First Warning System in the commercial markets continue. Jim Holmes, CEO of Lifeline Biotechnologies, reported that �efforts to identify a strategic partner interested in joining efforts to introduce the First Warning System�, a system designed to assist in the early detection of breast cancer, to the marketplace continue. We have met with prospective strategic partners; their response and interest is encouraging. We expect to continue discussions and hopefully a meaningful and common goal will be established.� Holmes continued to say that �management is establishing a platform for internal production and marketing, as well as development of the plan concurrent with prospects of accomplishing a relationship with a strategic partner. We have met with marketing consulting firms and investment banking consultants in an effort to consider the financing required for this internal commercialization program.� About Lifeline Biotechnologies, Inc: Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System�, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry billions of dollars annually, assuming the following are successfully completed: Clinical trials (if required) and filing and receiving a 510(k) from the FDA, and the product is successfully established in the marketplace. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.